Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAIH90)

• Drug Name: NPC-18166 Drug Info
• Synonyms: IDDB8389

Indication

Disease Entry	ICD 11	Status	REF
Psychotic disorder	6A20-6A25	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DMAIH90

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 2 receptor (5HT2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mianserin	DMVKA4O	Depression	6A70-6A7Z	Approved	[3]
Cyclobenzaprine	DM1YBRM	Depression	6A70-6A7Z	Approved	[4]
Perospirone	DMVHJLX	Psychotic disorder	6A20-6A25	Approved	[5]
Ketanserin	DMVLMW6	Hypertension	BA00-BA04	Approved	[6]
Bis(olanzapine) pamoate monohydrate	DME76AP	Psychotic disorder	6A20-6A25	Phase 3	[7]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[8]
Nexopamil	DML5S71	Hypertension	BA00-BA04	Phase 2	[9]
TGWOOAA	DMI57ZA	Generalized anxiety disorder	6B00	Phase 2	[10]
TGOF02N	DMQ6ANE	Schizophrenia	6A20	Phase 2	[11]
AMAP-102	DM7CD8Z	Arthritis	FA20	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 2 receptor (5HT2R)	TTYSN63	NOUNIPROTAC	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004563)
• [2] WO patent application no. 2004,0825,84, 5ht2c receptor antagonists in the treatment of schizophrenia.
• [3] 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6.
• [4] Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92.
• [5] Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8.
• [6] Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94.
• [10] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [11] Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals.
• [12] Clinical pipeline report, company report or official report of Anamar.